Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 15/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23384713 | 0.86 | ALDH1A1 (0.53) | MAPTALDH1A1KDM1AARDRD2 | |
| SCHEMBL30727376 | 0.86 | ALDH1A1 (0.53) | MAPTALDH1A1KDM1AARDRD2 | |
| SCHEMBL6101285 | 0.79 | ALDH1A1 (0.49) | MAPTALDH1A1KDM1AARDRD2 | |
| SCHEMBL20563792 | 0.76 | MAPT (0.42) | MAPTALDH1A1KDM1AARDRD2 | |
| SCHEMBL550208 | 0.71 | DRD2 (0.47) | MAPTALDH1A1ARDRD2DRD4 | |
| Trifluoroacetic Acid SCHEMBL29779525 | 0.70 | KDM4E (0.52) | MAPTALDH1A1KDM1ADRD2DRD4 | |
| Hydrochloric Acid SCHEMBL28923502 | 0.69 | DRD2 (0.45) | MAPTALDH1A1ARDRD2DRD4 | |
| Hydrochloric Acid SCHEMBL30142473 | 0.69 | DRD2 (0.45) | MAPTALDH1A1ARDRD2DRD4 | |
| SCHEMBL24680794 | 0.67 | PARP10 (0.56) | KDM4E | |
| SCHEMBL19410987 | 0.66 | AR (0.51) | MAPTALDH1A1ARDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010761-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | disclosed |